e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Asthma: outcomes of clinical trials and cohorts
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Budesoinde/formoterol: does eosinophil count cause different outcomes?
K. Dmytriiev (Vinnytsia, Ukraine), Y. Mostovoy (Vinnytsia, Ukraine), N. Slepchenko (Vinnytsia, Ukraine), N. Tsymbaliuk (Vinnytsia, Ukraine), A. Sidorov (Vinnytsia, Ukraine)
Source:
International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Session:
Asthma: outcomes of clinical trials and cohorts
Session type:
Thematic Poster
Number:
4245
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Dmytriiev (Vinnytsia, Ukraine), Y. Mostovoy (Vinnytsia, Ukraine), N. Slepchenko (Vinnytsia, Ukraine), N. Tsymbaliuk (Vinnytsia, Ukraine), A. Sidorov (Vinnytsia, Ukraine). Budesoinde/formoterol: does eosinophil count cause different outcomes?. 4245
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Peripheral eosinophil count as a biomarker for the management of COPD: not there yet
Source: Eur Respir J, 50 (5) 1702165; 10.1183/13993003.02165-2017
Year: 2017
Association between blood eosinophil count and control of allergic rhinitis: does it exist?
Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses
Year: 2019
How different operators performing sputum eosinophil differential cell counts may affect clinical decisions for severe asthma patients.
Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling
Year: 2020
Blood eosinophil count in the general population: typical values and potential confounders
Source: Eur Respir J, 55 (5) 1901874; 10.1183/13993003.01874-2019
Year: 2020
Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD?
Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights
Year: 2019
Definition of COPD phenotype depending on eosinophil count
Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease
Year: 2020
Could eosinophil / neutrophil ratio be used to determine treatment in COPD patients?
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018
Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no!
Source: Eur Respir J, 51 (5) 1800730; 10.1183/13993003.00730-2018
Year: 2018
An investigation of apoptotic eosinophil numbers in induced sputum: is there an association with asthma severity?
Source: Eur Respir J 2001; 18: Suppl. 33, 247s
Year: 2001
Late Breaking Abstract - Lack of stability of blood eosinophil counts in patients with COPD.
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease
Source: Eur Respir J 2016; 47:1299-1303
Year: 2016
Clinical variables and protein biomarkers associated with blood eosinophil count and asthma in young adults
Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough
Year: 2021
BAL cell counts in the diagnosis of lung diseases: is there a gain in information?
Source: Eur Respir J 2002; 20: Suppl. 38, 173s
Year: 2002
Elevated baseline blood eosinophil count is related to greater lung function decline over 20-years of follow-up.
Source: International Congress 2019 – Eosinophils and FeNO in airway diseases
Year: 2019
The blood eosinophil count as a biomarker in COPD
Source: International Congress 2015 – Individualised risk reduction strategies for patients with COPD
Year: 2015
The impact of high eosinophil count on hospitalizations in COPD patients
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018
High eosinophil counts predict decline in FEV
1
: results from the CanCOLD study
Source: Eur Respir J, 57 (5) 2000838; 10.1183/13993003.00838-2020
Year: 2021
Changes in eosinophil count and C reactive protein following treatment with mebendazole in patients with Toxocara-associated asthma
Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections
Year: 2010
Accuracy of blood eosinophil count in predicting sputum eosinophils in children with problematic severe asthma (PSA)
Source: Virtual Congress 2020 – Novel mechanisms and management of paediatric asthma
Year: 2020
Clinical significance of blood neutrophil differential count in patients with COPD
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept